^
    Back
    Association details:
    Biomarker:PLOD2 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Zhonghua Zhong Liu Za Zhi
    Title:

    [Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells]

    Published date:
    04/08/2020
    Excerpt:
    PLOD2 confers resistance to osimertinib in HCC827 cells…
    DOI:
    10.3760/cma.j.cn112152-20190322-00186